Comparative Pharmacology
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus HEMANGEOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus HEMANGEOL.
BETAXOLOL HYDROCHLORIDE vs HEMANGEOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Hemangeol (propranolol hydrochloride) is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors. In infantile hemangioma, the exact mechanism is not fully understood, but proposed actions include vasoconstriction, inhibition of angiogenesis by downregulating VEGF and bFGF, and induction of apoptosis in endothelial cells.
10-20 mg orally once daily; maximum 20 mg/day.
3 mg/kg/day orally divided into 2 doses for pediatric patients; adult use not indicated
None Documented
None Documented
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
3-4 hours in infants (0-1 year) and 3.5-4.5 hours in children (1-6 years); clinical context: requires TID dosing to maintain therapeutic effect.
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Primarily hepatic metabolism via UGT1A9 and CYP2C9; <5% excreted unchanged in urine. Biliary/fecal elimination of metabolites; exact % not defined.
Category C
Category C
Beta-Blocker
Beta-Blocker